Completed

Clinical and Molecular Manifestations of Heritable Connective Tissue Disorders

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Who is being recruted

Congenital Abnormalities+32

+ Abnormalities, Multiple

+ Dissection, Blood Vessel

See all eligibility criteria
How is the trial designed

Observational
Study Start: March 1997
See protocol details

Summary

Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 1997

Actual date on which the first participant was enrolled.

We will investigate the clinical manifestations and molecular genetic defects of heritable connective tissue disorders, concentrating on the Marfan, Stickler, and Ehlers-Danlos syndromes. Although each of these conditions has been known for many years, the full spectrum of the associated phenotypes continues to be expanded and the genetic etiology of these conditions has not been completely elucidated. In addition, many patients have features overlapping two or more of the described syndromes, precluding unequivocal diagnosis. The goals of this study are to further define and characterize the full phenotype and natural history of these disorders, and to perform genetic linkage, gene identification, mutation detection, and genotype/phenotype correlations in affected individuals and families. Individuals suspected to have Marfan, Stickler or Ehlers-Danlos syndrome or a closely related disorder, as well as interested family members, will be enrolled. Participants will undergo genetic analyses and periodic clinical assessment. The expected outcomes will be improved clinical descriptions of the conditions and gene and mutation identification with analysis of genotype/phenotype correlations.

NCT00001641
Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: March 4, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

900 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Congenital AbnormalitiesAbnormalities, MultipleDissection, Blood VesselAcute Aortic SyndromeAneurysmAortic DiseasesBone DiseasesBone Diseases, DevelopmentalCardiovascular DiseasesCollagen DiseasesHeart Defects, CongenitalHeart DiseasesHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersJoint DiseasesMusculoskeletal AbnormalitiesMusculoskeletal DiseasesNail DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSkin AbnormalitiesSkin DiseasesSkin Diseases, GeneticVascular DiseasesSkin and Connective Tissue DiseasesLimb Deformities, CongenitalCardiovascular AbnormalitiesHemostatic DisordersGenetic Diseases, InbornAortic DissectionConnective Tissue DiseasesEhlers-Danlos SyndromeMarfan SyndromeNail-Patella SyndromeArachnodactyly

Criteria

INCLUSION CRITERIA: Individuals and their family members will be offered enrollment if they have a suspected or established diagnosis of Marfan, Stickler, Ehlers-Danlos, or a closely related syndrome. Personal or family history of one or more of the following features in a pattern suggestive of a heritable connective tissue disorder: Marfanoid body habitus; Aortic dilatation and/or dissection; Ectopia lentis, detached retina, vitreous degeneration and/or early onset high myopia; Posterior cleft palate; joint laxity and/or dislocation; Premature osteoarthritis; Skin fragility, striae, easy bruisability and/or hyperextensibility; Pectus excavatum or carinatum; Scoliosis, spondylolisthesis, and/or dural ectasia; High frequency sensorineural hearing loss. EXCLUSION CRITERIA: Inability to provide informed consent.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Human Genome Research Institute (NHGRI)

Bethesda, United StatesOpen National Human Genome Research Institute (NHGRI) in Google Maps
CompletedOne Study Center